Compass Pathways PLC (CMPS)
AI stock analysis · as of May 24, 2026
Loading microstructure…
COMPASS Pathways is a clinical-stage UK biotech developing COMP360, a psilocybin-based therapy for treatment-resistant depression (TRD), with pipeline extensions into PTSD and anorexia. With two positive Phase 3 TRD readouts in hand and an NDA targeted for Q4 2026, the core investment question is whether the binary regulatory and commercial execution risk is adequately compensated at a ~$1.6B market cap after a steep rally, particularly given continued dilution and the novel supervised-administration commercial model.
This analysis is from May 24, 2026. Want the latest on CMPS, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Both pivotal Phase 3 trials (COMP005, COMP006) hit primary endpoints with p<0.001 and MADRS reductions of -3.6/-3.8 points, materially de-risking the regulatory path
- · Large underserved market: ~4M US TRD patients with only two approved therapies (esketamine, olanzapine/fluoxetine); FDA Breakthrough Therapy designation supports expedited review
- · Pipeline optionality via PTSD (FDA-accepted IND for COMP202 Phase 2b/3 targeting ~13M US patients) and anorexia, providing value beyond a single indication
- · Strong sentiment and tape support: news sentiment 0.72, strong-buy consensus across 15 analysts, stock near 52-week highs ($11.81 vs. $2.25 low), and reported political tailwinds for psychedelics
- · Commercial readiness work underway with US health systems to build scalable delivery infrastructure ahead of a potential late-2026 launch
Bear case
- · Pre-revenue with FY2025 net loss of -$287.9M (nearly 2x FY2024) and FCF of -$157M against only $149.6M cash — runway is short without continued raises
- · Heavy dilution: serial ATMs, 2023 PIPE, Jan 2025 and Feb 2026 underwritten offerings plus warrants; an additional $150M raise in late April adds to share count and caps upside
- · Single-asset concentration on COMP360 — any safety signal, FDA pushback, or DEA rescheduling delay (psilocybin is Schedule I) would be catastrophic
- · Novel commercial model requires 6-8 hour supervised sessions at certified sites with trained clinicians; reimbursement, throughput, and patient access are unproven
- · Hercules term loan (up to $100M) carries minimum cash covenants and milestone-dependent tranches, creating financing fragility if timelines slip
- · Valuation stretched after the rally; much of the Phase 3 success appears priced in, with at least one sell-side analyst flagging valuation concerns
Catalysts
- · COMP006 26-week durability data in early Q3 2026
- · Rolling NDA submission progress and FDA feedback through 2026, targeting Q4 2026 completion
- · DEA rescheduling actions or signals on psilocybin
- · PTSD COMP202 Phase 2b/3 initiation and interim updates
- · Additional commercial partnership announcements with US health systems and payors
- · Further capital raises (dilution risk) or non-dilutive financing/partnership deals
Key risks
- · FDA rejection, label restrictions, or REMS requirements that impair commercial viability
- · Failure to secure DEA rescheduling, blocking commercial sale even with FDA approval
- · Cash burn outpacing fundraising capacity, triggering Hercules covenant issues or distressed equity issuance
- · Negative durability data in COMP006 26-week readout undermining the TRD value proposition
- · Payor reimbursement falling short of the cost required to support supervised in-clinic administration
- · Continued shareholder dilution materially reducing per-share value even if COMP360 succeeds
Price target rationale
Risk-adjusted SOTP: assume ~$3-4B peak unadjusted enterprise value for COMP360 in TRD (peak sales ~$1.5-2B at 4-5x multiple), probability-weighted at ~50-55% for approval and commercial traction, plus modest pipeline credit for PTSD, less net dilution from ongoing raises and ~$150M+ additional capital needed pre-launch. That yields ~$15 per share on a fully diluted basis — above current $11.81 but well below the $22.20 street mean, reflecting valuation stretch after the rally and dilution drag.
On Wall Street's view (mixed): The $22.20 consensus target implies ~88% upside and reflects a credible probability-weighted approval scenario, but the $8-$70 range shows enormous disagreement, and the consensus appears to under-discount continued dilution and commercial-model uncertainty post-approval. We see fair value closer to current levels with skew to consensus only if Q3 2026 durability data and NDA acceptance go cleanly.
Latest filing (10-K)
COMPASS hit back-to-back Phase 3 wins in TRD with psilocybin therapy COMP360 and is racing toward a 2026 NDA submission, but remains a cash-burning pre-revenue company that must keep diluting shareholders to survive until potential approval.
COMPASS Pathways (CMPS) is a clinical-stage UK-based biotechnology company developing COMP360, a proprietary pharmaceutical-grade psilocybin formulation, for serious mental health conditions. The company has no product revenue and funds operations through equity offerings and debt. Its primary focus is treatment-resistant depression (TRD), with a secondary program in PTSD. It retains global development and commercialization rights to COMP360.
What the news says · bullish
CMPS has been on a sustained multi-month rally driven by a powerful confluence of catalysts: positive Phase 3 COMP360 data, an accelerated/priority FDA review, an earnings beat with a swing to Q1 2026 profitability, and political tailwinds from reported Trump administration support for psychedelics. Analyst price targets have been raised (TD Cowen at $29, consensus near $21) and the stock has reached two-year highs, with retail and institutional momentum both building. The main counterweights are a $150M dilutive equity offering in late April and valuation-stretch concerns flagged by at least one analyst, suggesting the easy money may already be priced in. The FDA catalyst remains the dominant near-term binary event, making this a high-reward but high-risk setup typical of late-stage biotech. Coverage is reasonably broad and consistent, lending credibility to the bullish read.
This analysis is from May 24, 2026. Markets move. Get the current read on CMPS and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.